Kronos Bio
Clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target dysregulated transcription to treat cancer and other serious diseases.
Website
https://www.kronosbio.comLocation
San Mateo, California, USA
Founded
2017
Investors
1
Categories
biotech, precision-medicine, oncology, transcription-factors, therapeutics
Notes
Kronos Bio is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies that modulate transcription to address the underlying drivers of disease. The company's approach targets transcription factors, which are proteins that control gene expression and are frequently dysregulated in cancer but have historically been difficult to target with small molecule drugs.
The company went public in October 2020 on NASDAQ under the ticker KRON. Kronos Bio's lead programs focus on targeting MYC and other oncogenic transcription factors.
Team
- Norbert Bischofberger, Ph.D. - President & Chief Executive Officer (former EVP R&D at Gilead Sciences)
- LinkedIn: linkedin.com/in/norbert-bischofberger
- Nicole Onetto, M.D. - Chief Medical Officer
- Christopher J. Dinsmore, Ph.D. - Chief Scientific Officer
- Michael Rosenblum - Chief Financial Officer
Additional Research Findings
- Founded in 2017
- Listed on NASDAQ (KRON) since October 2020
- Headquarters in San Mateo, California
- Focus on transcription factor targeting in oncology
- Lead program KB-0742 targets CDK9 for solid tumors
- Also developing programs targeting MYC-driven cancers
- Scientific founders include Angela Koehler, Ph.D. (MIT) and James Bradner, M.D.
- Backed by investors including Polaris Partners, GV, and Omega Funds
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |